$52.79 +0.73 (%) Cepheid Inc - NASDAQ

Nov. 21, 2014 | 04:00 PM

Partner Headlines

  1. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga | Nov. 13, 2014 | 07:01AM EST
  2. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD | Nov. 6, 2014 | 18:41PM EST
  3. Stocks Fight Back To Finish Mixed

    IBD | Oct. 27, 2014 | 16:20PM EST
  4. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD | Oct. 27, 2014 | 15:00PM EST
  5. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD | Oct. 17, 2014 | 16:31PM EST
  6. CEPHEID

    IBD | Oct. 16, 2014 | 18:49PM EST
  7. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga | Oct. 1, 2014 | 16:06PM EST
  8. UPDATE: ISI Group Upgrades Cepheid

    Benzinga | Aug. 11, 2014 | 15:47PM EST
  9. CEPHEID

    IBD | Jul. 17, 2014 | 18:49PM EST
  10. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD | Feb. 4, 2014 | 18:42PM EST
  11. Alexion Takes Off On Outlook

    IBD | Jan. 30, 2014 | 18:52PM EST
  12. Three Medical Tech Names To Watch In Healthcare Space

    IBD | Jan. 3, 2014 | 18:22PM EST
  13. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD | Dec. 23, 2013 | 16:45PM EST
  14. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market Leader Position

    Benzinga | Dec. 18, 2013 | 09:34AM EST
  15. Five Medical Stocks Leaders Trade Near New Highs

    IBD | Nov. 22, 2013 | 18:49PM EST
  16. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD | Nov. 11, 2013 | 17:13PM EST
  17. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining Revenue Multiple

    Benzinga | Oct. 4, 2013 | 11:53AM EST
  18. Benzinga's Top Downgrades

    Benzinga | Oct. 4, 2013 | 07:34AM EST
  19. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga | Oct. 1, 2013 | 08:54AM EST
  20. Benzinga's Top Downgrades

    Benzinga | Oct. 1, 2013 | 08:17AM EST
  21. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' by FDA

    Benzinga | Aug. 28, 2013 | 07:04AM EST
  22. Cepheid Announces Board of Directors Changes

    Benzinga | Feb. 14, 2013 | 09:09AM EST
  23. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate Complexity' by FDA

    Benzinga | Jan. 15, 2013 | 00:13AM EST
  24. Medtech Stocks Moving As Conference Makes Waves

    IBD | Jan. 8, 2013 | 07:25AM EST
  25. Medtech Stocks Moving As Conference Makes Waves

    IBD | Jan. 8, 2013 | 07:21AM EST
  26. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ~$92M vs $93.5M Est, EPS $0.10-0.12

    Benzinga | Jan. 8, 2013 | 01:36AM EST
  27. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga | Jan. 4, 2013 | 03:15AM EST
  28. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on Cepheid

    Benzinga | Dec. 28, 2012 | 03:46AM EST
  29. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga | Dec. 28, 2012 | 03:44AM EST
  30. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga | Dec. 28, 2012 | 03:44AM EST
  31. US Stock Futures Down Ahead Of Economic Data

    Benzinga | Dec. 27, 2012 | 23:18PM EST
  32. Stocks To Watch For December 28, 2012

    Benzinga | Dec. 27, 2012 | 18:42PM EST
  33. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga | Dec. 27, 2012 | 09:13AM EST
  34. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

    Benzinga | Dec. 16, 2012 | 23:47PM EST
  35. Look At That Base: If You Can't Name It, Don't Buy It

    IBD | Dec. 4, 2012 | 10:19AM EST
  36. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of Catalysts

    Benzinga | Nov. 19, 2012 | 05:02AM EST
  37. Benzinga's Top Downgrades

    Benzinga | Nov. 19, 2012 | 00:24AM EST
  38. Benzinga's Top Upgrades

    Benzinga | Nov. 16, 2012 | 00:07AM EST
  39. CEPHEID Reports Operating Results (10-Q)

    GuruFocus | Nov. 2, 2012 | 13:08PM EST
  40. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst Day Takeaways

    Benzinga | Sep. 28, 2012 | 08:19AM EST
  41. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 PT Post Analyst Day

    Benzinga | Sep. 28, 2012 | 07:45AM EST
  42. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga | Sep. 28, 2012 | 05:08AM EST
  43. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst Day

    Benzinga | Sep. 28, 2012 | 02:40AM EST
  44. Benzinga Mid-Afternoon Market Update

    Benzinga | Sep. 27, 2012 | 09:53AM EST
  45. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard (HPQ) on the move

    MarketIntelligenceCenter | Sep. 27, 2012 | 08:35AM EST
  46. Benzinga Mid-Day Market Update

    Benzinga | Sep. 27, 2012 | 08:20AM EST
  47. Mid-Morning Market Update

    Benzinga | Sep. 27, 2012 | 04:24AM EST
  48. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative Pre-Announcement

    Benzinga | Sep. 27, 2012 | 02:22AM EST
  49. Benzinga's Top Initiations

    Benzinga | Sep. 26, 2012 | 01:36AM EST
  50. A Peek Into The Market Before The Trading Starts

    Benzinga | Sep. 26, 2012 | 01:34AM EST
Trading Center